4-氨基-1-乙基-1H-吡唑-5-羧酸甲酯 | 923283-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-氨基-1-乙基-1H-吡唑-5-羧酸甲酯
• 英文名称: methyl 4-amino-1-ethyl-1H-pyrazole-5-carboxylate
• 英文别名: methyl 4-amino-2-ethylpyrazole-3-carboxylate
• CAS: 923283-57-2
• 化学式: C₇H₁₁N₃O₂
• 分子量: 169.183
• InChiKey: JKUAKLZRAQWJFV-UHFFFAOYSA-N

物化性质

• 沸点：
  298.6±20.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氨基-1-乙基-1H-吡唑-5-羧酸甲酯 在 4-二甲氨基吡啶 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 74.0h， 生成 4-benzyl-1-ethyl-5,6-dihydro-1H-pyrazolo[4,3-b]pyridin-7(4H)-one
  参考文献：
  名称：

  ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE

  摘要：

  公开号：

  EP3287441B1
• 作为产物：
  描述：

  1-乙基-4-硝基-1H-吡唑-5-羧酸甲酯 在 钯 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以to give the title compound (1.8 g)的产率得到4-氨基-1-乙基-1H-吡唑-5-羧酸甲酯
  参考文献：
  名称：

  FUSED HETEROCYCLIC COMPOUNDS

  摘要：

  本发明提供一种具有PDE 10A抑制作用的化合物，可用作预防或治疗精神分裂症等药物。化合物表示为公式（1'）：其中，环A'表示可选取取代的吡啶环、可选取取代的吡嗪环、嘧啶环或吡嗪环，R1'表示（1）其中，R1a'表示可选取取代的苯基或可选取取代的5-至10-成员杂环基，环B2表示键、-S-、-O-、可选取取代的亚甲基基或-NRa'（Ra'表示氢原子或可选取取代的C1-6烷基基），环B1'表示可选进一步取代的6-至10-成员芳香烃环或可选进一步取代的5-至10-成员芳香杂环环，或者，L'和R1a'可取代成为可选取代的双环或三环融合杂环基，或（2），其中，R1b'表示可选取取代的苯基或可选取取代的5-至10-成员杂环基，环B2'表示可选取取代的苯环、可选取取代的吡啶环、可选取取代的嘧啶环、可选取取代的吡嗪环或可选取取代的吡嗪环，环D'表示可选进一步取代的5-或6-成员环，R2'表示氢原子或取代基，X'表示═N-或═CRb'-（Rb'表示氢原子或取代基），- - - - - 表示当X'为═CRb'时，Rb'和R2'可与它们各自相邻的碳原子和氮原子一起形成可选取代的5-至7-成员环，或其盐。

  公开号：

  US20130172292A1

文献信息

• [EN] FUSED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2012018909A1

  公开（公告）日：2012-02-09

  The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1'): wherein, Ring A' represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1' represents (1) wherein, R1a' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, -S-, -0-, -CO-, an optionally substituted methylene group, or -NRa'- (Ra' represents a hydrogen atom, or an optionally substituted C1-6 alkyl group), and Ring B1' represents an optionally further substituted 6- to 10- membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L' and R1a' may be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, R1b' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2' represents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D' represents an optionally further substituted 5- or 6- membered ring, R2' represents a hydrogen atom, or a substituent, X' represents =N- or =CRb'- (Rb' represents a hydrogen atom, or a substituent), _ _ _ _ _ represents that Rb' and R2' may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X' is =CRb'-, or a salt thereof.

  本发明提供了一种具有PDE 10A抑制作用的化合物，可用作预防或治疗精神分裂症等疾病的药物。化合物的结构如下（1'）：其中，环A'代表可选择取代的吡啶环、可选择取代的吡啉环、嘧啶环或吡嗪环，R1'代表（1）其中，R1a'代表可选择取代的苯基或可选择取代的5-至10-成员杂环基，环B2代表键、-S-、-O-、-CO-、可选择取代的亚甲基基团或-NRa'-（Ra'代表氢原子或可选择取代的C1-6烷基基团），环B1'代表可选择进一步取代的6-至10-成员芳香碳氢环、或可选择进一步取代的5-至10-成员芳香杂环环，或者，L'和R1a'可以结合形成可选择取代的双环或三环融合杂环基，或（2）其中，R1b'代表可选择取代的苯基或可选择取代的5-至10-成员杂环基，环B2'代表可选择取代的苯环、可选择取代的吡啶环、可选择取代的嘧啶环、可选择取代的吡嗪环或可选择取代的吡啉环，环D'代表可选择进一步取代的5-或6-成员环，R2'代表氢原子或取代基，X'代表=N-或=CRb'-（Rb'代表氢原子或取代基），_ _ _ _ _代表Rb'和R2'可能形成，与它们各自相邻的碳原子和氮原子一起，当X'为=CRb'-时，形成可选择取代的5-至7-成员环，或其盐。
• Pyrazolo pyrimidines useful as aurora kinase inhibitors
  申请人：Oslob D. Johan

  公开号：US20070027166A1

  公开（公告）日：2007-02-01

  The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R 2 , R 4 , X 1A , X 2A , X 1B , X 2B , L 1 , L 2 , Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

  本发明提供具有以下结构的化合物：其中A-B一起代表以下结构之一：其中之一是双键，根据价性而定；而R2、R4、X1A、X2A、X1B、X2B、L1、L2、Y和Z如此处所定义，以及其制药组合物，如此处总体描述和所述的亚类，这些化合物可用作蛋白激酶（例如Aurora）的抑制剂，因此可用于例如治疗由Aurora介导的疾病。
• FUSED HETEROCYCLIC COMPOUNDS
  申请人：Raker Joseph

  公开号：US20130172292A1

  公开（公告）日：2013-07-04

  The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1′): wherein, Ring A′ represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1′ represents (1) wherein, R 1a′ represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, —S—, -0-, —CO—, an optionally substituted methylene group, or —NR a′ -(R a′ represents a hydrogen atom, or an optionally substituted C 1-6 alkyl group), and Ring B 1′ represents an optionally further substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L′ and R 1a′ may be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, R 1b′ represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B 2′ represents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D′ represents an optionally further substituted 5- or 6-membered ring, R 2′ represents a hydrogen atom, or a substituent, X′ represents ═N— or ═CR b′ —(R b′ represents a hydrogen atom, or a substituent), - - - - - represents that R b′ and R 2′ may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X′ is ═CR b′ , or a salt thereof.

  本发明提供一种具有PDE 10A抑制作用的化合物，可用作预防或治疗精神分裂症等药物。化合物表示为公式（1'）：其中，环A'表示可选取取代的吡啶环、可选取取代的吡嗪环、嘧啶环或吡嗪环，R1'表示（1）其中，R1a'表示可选取取代的苯基或可选取取代的5-至10-成员杂环基，环B2表示键、-S-、-O-、可选取取代的亚甲基基或-NRa'（Ra'表示氢原子或可选取取代的C1-6烷基基），环B1'表示可选进一步取代的6-至10-成员芳香烃环或可选进一步取代的5-至10-成员芳香杂环环，或者，L'和R1a'可取代成为可选取代的双环或三环融合杂环基，或（2），其中，R1b'表示可选取取代的苯基或可选取取代的5-至10-成员杂环基，环B2'表示可选取取代的苯环、可选取取代的吡啶环、可选取取代的嘧啶环、可选取取代的吡嗪环或可选取取代的吡嗪环，环D'表示可选进一步取代的5-或6-成员环，R2'表示氢原子或取代基，X'表示═N-或═CRb'-（Rb'表示氢原子或取代基），- - - - - 表示当X'为═CRb'时，Rb'和R2'可与它们各自相邻的碳原子和氮原子一起形成可选取代的5-至7-成员环，或其盐。
• Fused heterocyclic compounds
  申请人：Raker Joseph

  公开号：US09029536B2

  公开（公告）日：2015-05-12

  The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1′): wherein, Ring A′ represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1′ represents (1) wherein, R1a′ represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, —S—, -0-, —CO—, an optionally substituted methylene group, or —NRa′— (Ra′ represents a hydrogen atom, or an optionally substituted C1-6 alkyl group), and Ring B1′ represents an optionally further substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L′ and R1a′ may be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, R1b′ represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2′ represents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D′ represents an optionally further substituted 5- or 6-membered ring, R2′ represents a hydrogen atom, or a substituent, X′ represents ═N— or ═CRb′—(Rb′ represents a hydrogen atom, or a substituent), - - - - - represents that Rb′ and R2′ may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X′ is ═CRb′, or a salt thereof.

  本发明提供了一种具有PDE 10A抑制作用的化合物，可用作预防或治疗精神分裂症等药物。化合物的结构式为（1'）：其中，环A'表示可选取取代的吡啶环、可选取取代的吡嗪环、嘧啶环或吡嗪环，R1'表示（1），其中R1a'表示可选取取代的苯基或可选取取代的5-至10-成员杂环基，环B2表示键、-S-、-O-、可选取取代的亚甲基基或-NRa'-(Ra'表示氢原子或可选取取代的C1-6烷基基)，环B1'表示可选取进一步取代的6-至10-成员芳香碳环或可选取进一步取代的5-至10-成员芳香杂环，或者，L'和R1a'可取代成为可选取代的双环或三环融合杂环基，或（2），其中R1b'表示可选取取代的苯基或可选取取代的5-至10-成员杂环基，环B2'表示可选取取代的苯环、可选取取代的吡啶环、可选取取代的嘧啶环、可选取取代的吡嗪环或可选取取代的吡嗪嗪环，环D'表示可选进一步取代的5-或6-成员环，R2'表示氢原子或取代基，X'表示═N-或═CRb'-（Rb'表示氢原子或取代基），- - - - - 表示当X'为═CRb'时，Rb'和R2'可以与它们各自相邻的碳原子和氮原子一起形成可选取代的5-至7-成员环，或其盐。
• PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF
  申请人：Jiangsu Hengrui Pharmaceuticals Co., Ltd.

  公开号：EP4063363A1

  公开（公告）日：2022-09-28

  Disclosed is a pyrazolo-heteroaryl derivative, a preparation method therefor, and medical use thereof. In particular, the present invention relates to a pyrazolo-heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, particularly as ATR kinase inhibitor and in the preparation of drugs for the treatment and/or prevention of hyperproliferative diseases. The definition of each group in the general formula (I) is identical as in the specification.

  本发明公开了一种吡唑杂环衍生物及其制备方法和医药用途。具体而言，本发明涉及一种如通式（I）所示的吡唑杂环衍生物、其制备方法、含有该衍生物的药物组合物以及其作为治疗剂的用途，特别是作为ATR激酶抑制剂和制备用于治疗和/或预防过度增殖性疾病的药物。通式（I）中每个基团的定义与说明书中相同。